The use of sodium-glucose cotransporter type 2 inhibitors for the purpose of treating the chronic cardiac failure in oncology patients receiving cardiotoxic chemotherapy: preliminary results
- Authors: Peresada A.K.1, Dundua D.P.1, Kedrova A.G.1, Oleinikova I.N.1, Salimova A.V.1
-
Affiliations:
- Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
- Issue: Vol 15, No 3 (2024)
- Pages: 7-16
- Section: Original Study Articles
- URL: https://journal-vniispk.ru/clinpractice/article/view/268715
- DOI: https://doi.org/10.17816/clinpract629938
- ID: 268715
Cite item
Abstract
BACKGROUND: Chronic cardiac failure belongs to the most threatening and delayed manifestations of cardiotoxicity in oncology patients receiving the treatment with antitumor medicines. As of today, only two groups of drugs were proven to have significant cardioprotective effects in these categories of patients: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-adrenergic blockers. Recently, the first data were published on the successful use of sodium-glucose cotransporter type 2 inhibitors in patients with chronic cardiac failure, receiving anthracycline therapy.
AIM: optimization of cardioprotective therapy in the treatment of chronic cardiac failure in oncology patients receiving cardiotoxic chemotherapy.
METHODS: A prospective observational open-label research was carried out with an enrollment of 116 oncology patients with verified chronic cardiac failure, which were receiving cardiotoxic chemotherapy, of which 60 patients of the control group were receiving double cardioprotective therapy (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers) and the 56 patients of the test group were receiving similar therapy with an addition of Dapagliflozin at a dosage of 10 mg once daily in the morning. The controls of the results were conducted in 6 months by means of laboratory and instrumental examinations, as well as by using additional methods of controlling the results.
RESULTS: The groups compared did not differ by the combined primary clinical endpoint (the rate of hospitalizations due to cardio-vascular reasons, the refusal to undergo chemotherapy for the reason of chronic cardiac failure progression and the safety of using the drug products: the presence of urinary tract infections and sepsis), but they differed by the surrogate clinical endpoints that included the dynamic trend of the levels of the groups compared did not differ by the combined primary clinical endpoint (the rate of hospitalizations due to cardio-vascular reasons, the refusal to undergo chemotherapy for the reason of chronic cardiac failure progression and the safety of using the drug products: the presence of urinary tract infections and sepsis), but they differed by the surrogate clinical endpoints that included the dynamic trend of the levels of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and the global longitudinal strain (GLS) of the left ventricle, determined within the timeframes established for the research — before the initiation of chemotherapy and in 6 months. The patients that have passed all the control tests (n=47), after the end of the 6 months period, underwent a comparison of the levels of troponin Т, left ventricle ejection fraction (LVEF), NT-proBNP and GLS. It was found that the dynamic changes of troponin T levels in both groups did not significantly differ (p=0,260), as well as the LVEF indicator (p=0.340), while the NT-proBNP level was significantly decreasing in the test group — by 7.8% comparing to the control group (p=0.006). Comparable data were obtained for the GLS (the decrease in the test group by 6.5% in relative values) comparing to the control group (p=0.008). In 22/47 (46,8%) patients, chronic cardiac failure was diagnosed before the initiation of chemotherapy, in 25/47 (53,2%), chronic cardiac failure was developing during the antitumor medication therapy. In both groups, a total of 17 (16%) fatal outcomes were registered, none of which was caused by the cardiac failure.
CONCLUSION: We suppose that the decrease in the levels of the cardiac failure marker and the less intensive impairment of the left ventricle longitudinal strain with a background of adding sodium-glucose cotransporter type 2 inhibitors to baseline therapy for chronic cardiac failure in oncology patients receiving cardiotoxic chemotherapy, reflects their cardioprotective potential. Thus, the sodium-glucose cotransporter type 2 inhibitor Dapagliflozin slows down the progression of chronic cardiac failure in oncology patients receiving cardiotoxic chemotherapy.
Full Text
##article.viewOnOriginalSite##About the authors
Anton K. Peresada
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
Author for correspondence.
Email: tony.peresada@yandex.ru
ORCID iD: 0000-0001-7128-0183
SPIN-code: 2518-6553
Russian Federation, Moscow
David P. Dundua
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
Email: david.doundoua@gmail.com
ORCID iD: 0000-0001-7345-0385
MD, PhD, Professor
Russian Federation, MoscowAnna G. Kedrova
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
Email: kedrova.anna@gmail.com
ORCID iD: 0000-0003-1031-9376
SPIN-code: 3184-9760
MD, PhD, Professor
Russian Federation, MoscowIrina N. Oleinikova
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
Email: i.n.oleynikova@yandex.ru
ORCID iD: 0000-0002-2595-1908
SPIN-code: 9272-9336
PhD
Russian Federation, MoscowAlisa V. Salimova
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies
Email: misa97_97@mail.ru
ORCID iD: 0009-0000-8381-6627
Russian Federation, Moscow
References
- Zamorano JL, Lancellotti P, Muñoz RD, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: The task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). EurHeart J. 2016; 37(36):2768–2801. doi: 10.1093/eurheartj/ehw211
- Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(9): 547–558. doi: 10.1038/nrcardio.2015.65
- Seicean A, Alan N. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: Follow-up study of heart failure. Circ Heart Fail. 2013;6(3): 420–426. doi: 10.1161/CIRCHEARTFAILURE.112.000055
- Livi L, Barletta G, Martella F, et al. Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: A randomized clinical trial. JAMA Oncol. 2021;7(10):1544–1549. EDN: LOSDWK doi: 10.1001/jamaoncol.2021.3395
- Виценя М.В., Потехина А.В., Гаврюшина С.В., и др. Профилактика и лечение дисфункции левого желудочка и сердечной недостаточности, связанных с противоопухолевой терапией: возможности и перспективы // Эффективная фармакотерапия. 2020. Т. 16, № 18. С. 108–120. [Vitsenya MV, Potekhina AV, Gavryushina SV, et al. Prevention and treatment of left ventricular dysfunction and heart failure associated with antitumor therapy: Opportunities and prospects. Effect Pharmacother. 2020;16(18):108–120]. EDN: XQPBGK doi: 10.33978/2307-3586-2020-16-18-108-120
- Vitsenya MV, Potekhina AV, Stukalova OV. Onset of heart failure after anthracycline therapy in the adult: Treatment and expectations for recovery. In: Steingart RM, Liu JE, eds. Atlas of imaging in cardio-oncology. Springer, Cham; 2021. doi: 10.1007/978-3-030-70998-3_27
- Gongora CA, Drobni ZD, Silva TQ. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracycline. JACC Heart Fail. 2022;10(8):559–567. EDN: HFMCAZ doi: 10.1016/j.jchf.2022.03.006
- McMurray JJ, de Mets DL, Inzucchi SE, et al. The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: Baseline characteristics. Eur J Heart Fail. 2019;21(11): 1402–1411. EDN: DJXUII doi: 10.1002/ejhf.1548
- Joachim A, Joe-Elie S, Javid M, et al. Identification of anticancer drugs associated with atrial fibrillation: Analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):312–320. doi: 10.1093/ehjcvp/pvaa037
- Pandey AK, Singhi EK, Arroyo JP, et al. Mechanisms of VEGF (Vascular Endothelial Growth Factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71(2): e1–e8. EDN: GSHTVT doi: 10.1161/hypertensionaha.117.10271
- Raimondi S, Botteri E, Munzone E, et al. Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis. Int J Cancer. 2016;139(1):212–219. doi: 10.1002/ijc.30062
- Slamon D, Eiermann W, Robert N, et al.; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14): 1273–1283. doi: 10.1056/NEJMoa0910383
- McMurray JJ, Docherty KF, de Boer RA, et al. Effect of dapagliflozin versus placebo on symptoms and 6-minute walk distance in patients with heart failure: The DETERMINE randomized clinical trials. Circulation. 2024;149(11):825–838. EDN: JUOOWC doi: 10.1161/circulationaha.123.065061
Supplementary files
